These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 16049867)

  • 1. GEM-231 (Hybridon).
    Blay J
    IDrugs; 2000 Sep; 3(9):1075-80. PubMed ID: 16049867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology evaluation: GEM-231, Hybridon Inc.
    Blay J
    Curr Opin Mol Ther; 2000 Aug; 2(4):468-72. PubMed ID: 11249779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology evaluation: GEM-92, Hybridon Inc.
    Zheng R
    Curr Opin Mol Ther; 1999 Aug; 1(4):521-3. PubMed ID: 11713769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endostatin (EntreMed).
    Grosios K
    IDrugs; 2000 Jul; 3(7):799-810. PubMed ID: 16080055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
    Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
    Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral heparin (Emisphere).
    Dunn A
    IDrugs; 2000 Jul; 3(7):817-24. PubMed ID: 16080057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
    Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
    Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AG-3340 (Agouron Pharmaceuticals Inc).
    Griffioen AW
    IDrugs; 2000 Mar; 3(3):336-45. PubMed ID: 16103944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaxanib (SUGEN).
    Sakamoto KM
    IDrugs; 2001 Sep; 4(9):1061-7. PubMed ID: 15965852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: HYB-2055, Hybridon.
    Switaj T; Lasek W
    Curr Opin Mol Ther; 2005 Aug; 7(4):376-83. PubMed ID: 16121704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
    Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
    Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.